C
Curamir Therapeutics
Curamir Therapeutics, Inc. – Finding RNA-targeted cures for cancer
About Curamir Therapeutics
Curamir Therapeutics Inc., based in Woburn, MA, is a biotechnology firm focused on developing microRNA (miRNA) based cancer therapeutics. Founded in 2019, the company leverages over a decade of research in miRNA and cancer biology, led by Professor Jingfang Ju from Stony Brook University. Curamir operates within the oncology sector, targeting RNA to create transformative therapies aimed at improving patient outcomes. The company is incubated through a licensing collaboration with the State University of New York (SUNY) and was co-founded by experts in gene regulation and translational medicine, including Dr. James D. Watson and Dr. Lan Bo Chen. Curamir's business model centers on its proprietary miRNA engineering platform, which enhances the safety, potency, and stability of its therapeutic offerings. The firm generates revenue through the development and potential commercialization of these targeted cancer treatments. Curamir's leadership comprises a team of distinguished scientists and industry veterans, positioning the company at the forefront of cancer biology and genetics.
Source: Dealroom company dataNews
Open roles
Curamir Therapeutics in the Woburn ecosystem
The Curamir Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Delos Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Curamir Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Curamir Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.